Prior to co-founding twoXAR, Andrew held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew developed the company's proprietary algorithm and as Chief Executive Officer is focused on overall company strategy, product development and fundraising. Andrew studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.
twoXAR Pharmaceuticals is an AI-driven drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 18 diseases, six of which have been licensed to larger pharmaceutical companies. twoXAR’s unique technology and process saves years in drug development while generating 30x the hit rate at in vivo efficacy milestones over traditional approaches.